China Universal Asset Management Co. Ltd. Raises Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

China Universal Asset Management Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 10.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,092 shares of the biopharmaceutical company’s stock after buying an additional 1,150 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Agios Pharmaceuticals were worth $397,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the period. CWM LLC lifted its holdings in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the last quarter. Quest Partners LLC boosted its position in shares of Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,283 shares in the last quarter. KBC Group NV grew its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at approximately $146,000.

Wall Street Analyst Weigh In

Several research firms have commented on AGIO. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Raymond James restated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Finally, Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Stock Down 0.4 %

AGIO opened at $34.39 on Monday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 3.03 and a beta of 0.87. The firm has a 50 day moving average price of $40.30 and a 200-day moving average price of $44.36. Agios Pharmaceuticals, Inc. has a twelve month low of $22.23 and a twelve month high of $62.58.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.